NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure
NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
The MAMMOTH study: Monoclonal Antibodies in Multiple Myeloma: Outcomes after Therapy Failure